NuVasive (NASDAQ: NUVA) had its target price upped by Robert W. Baird from $19.00 to $22.00 in a research note issued to investors on Wednesday. The firm currently has an outperform rating on the stock.

A number of other firms have also recently commented on NUVA. Analysts at Mizuho downgraded shares of NuVasive from a buy rating to a neutral rating in a research note to investors on Wednesday. They now have a $20.00 price target on the stock. They noted that the move was a valuation call. Separately, analysts at JPMorgan Chase raised their price target on shares of NuVasive to $20.00 in a research note to investors on Tuesday. Finally, analysts at Zacks upgraded shares of NuVasive from a neutral rating to an outperform rating in a research note to investors on Wednesday, January 16th. They now have a $18.80 price target on the stock.

Eight research analysts have rated the stock with a buy rating, one has assigned an overweight rating, and thirteen have assigned a hold rating to the company’s stock. The company currently has an average rating of overweight and a consensus price target of $21.86.

NuVasive traded down 0.05% on Wednesday, hitting $18.56. NuVasive has a 1-year low of $12.35 and a 1-year high of $25.99. The stock’s 50-day moving average is currently $17.50. The company has a market cap of $809.7 million and a price-to-earnings ratio of 265.29.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.